(NASDAQ: AMRN) Amarin's forecast annual revenue growth rate of -1.92% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 7.42%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.78%.
Amarin's revenue in 2026 is $186,232,000.On average, 4 Wall Street analysts forecast AMRN's revenue for 2026 to be $76,384,393,215, with the lowest AMRN revenue forecast at $71,019,193,315, and the highest AMRN revenue forecast at $81,175,052,023. On average, 4 Wall Street analysts forecast AMRN's revenue for 2027 to be $76,190,063,140, with the lowest AMRN revenue forecast at $68,159,161,558, and the highest AMRN revenue forecast at $83,836,529,138.
In 2028, AMRN is forecast to generate $73,879,225,073 in revenue, with the lowest revenue forecast at $65,370,947,437 and the highest revenue forecast at $82,062,211,061.